Clinical Trial Update: An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis [Phase 3]

View source ↗

Summary

An open-label, dose-titration Phase 3 study evaluating sevelamer carbonate in hyperphosphatemic CKD patients not on dialysis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• SEVELAMER CARBONATE (sevelamer carbonate)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Chronic Kidney Disease, Hyperphosphatemia | Phase 3 | Status: COMPLETED